Merck (MRK)
Develops oncology medicines, vaccines, cardiopulmonary therapies, and animal-health products worldwide.
$147.28
vs last close−3.64 (−2.41%)
Something off on this page? Send us feedback.
Next report
Oct 29, 26
in 36 days
EPS estimate
$2.21
Revenue estimate
$17.31B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Aug '26Oct '26
Reported$1.72$2.22$2.13$2.58$2.04−$1.28−$0.13Pending
Estimate$1.85$2.13$2.03$2.36$2.01−$1.47−$0.27$2.21
Surprise−7.0%+4.2%+4.9%+9.3%+1.5%+12.9%+51.9%—
RevenueReportedEstimate
Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Aug '26Oct '26
Reported$15.62B$15.53B$15.81B$17.28B$16.40B$16.29B$16.61BPending
Estimate$15.48B$15.34B$15.86B$16.98B$16.20B$15.85B$16.37B$17.31B
Surprise+0.9%+1.2%−0.4%+1.8%+1.2%+2.8%+1.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $2.46 | — | — |
| Sep 2028 | $2.74 | — | — |
| Jun 2028 | $2.31 | — | — |
| Mar 2028 | $2.30 | — | — |
| Dec 2027 | $2.35 | — | — |
| Sep 2027 | $2.56 | — | — |
| Jun 2027 | $2.24 | — | — |
| Mar 2027 | $2.21 | — | — |
| Dec 2026 | $1.96 | — | — |
| Oct 2026 | $2.21 | — | — |
| Aug 2026 | −$0.27 | −$0.13 | +51.9% |
| Apr 2026 | −$1.47 | −$1.28 | +12.9% |
| Feb 2026 | $2.01 | $2.04 | +1.5% |
| Oct 2025 | $2.36 | $2.58 | +9.3% |
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $2.46 | — | — | $19.00B | — | — | — |
| Sep 2028 | $2.74 | — | — | $19.68B | — | — | — |
| Jun 2028 | $2.31 | — | — | $17.92B | — | — | — |
| Mar 2028 | $2.30 | — | — | $17.40B | — | — | — |
| Dec 2027 | $2.35 | — | — | $18.29B | — | — | — |
| Sep 2027 | $2.56 | — | — | $18.67B | — | — | — |
| Jun 2027 | $2.24 | — | — | $17.23B | — | — | — |
| Mar 2027 | $2.21 | — | — | $16.59B | — | — | — |
| Dec 2026 | $1.96 | — | — | $16.90B | — | — | — |
| Oct 29, 2026 | $2.21 | — | — | $17.31B | — | — | — |
| Aug 4, 2026 | −$0.27 | −$0.13 | +51.9% | $16.37B | $16.61B | +1.5% | +0.2% |
| Apr 30, 2026 | −$1.47 | −$1.28 | +12.9% | $15.85B | $16.29B | +2.8% | −1.6% |
| Feb 3, 2026 | $2.01 | $2.04 | +1.5% | $16.20B | $16.40B | +1.2% | +2.2% |
| Oct 30, 2025 | $2.36 | $2.58 | +9.3% | $16.98B | $17.28B | +1.8% | −0.4% |
| Jul 29, 2025 | |||||||
| Apr 24, 2025 | |||||||
| Feb 4, 2025 | |||||||
| Oct 31, 2024 | |||||||
| Jul 30, 2024 | |||||||
| Apr 25, 2024 | |||||||
| Feb 1, 2024 | |||||||
| Oct 26, 2023 | |||||||
| Aug 1, 2023 | |||||||
| Apr 27, 2023 | |||||||
| Feb 2, 2023 | |||||||
| Oct 27, 2022 | |||||||
| Jul 28, 2022 | |||||||
| Apr 28, 2022 | |||||||
| Feb 3, 2022 | |||||||
| Oct 28, 2021 | |||||||
| Jul 29, 2021 | |||||||
| Apr 29, 2021 | |||||||
| Feb 4, 2021 | |||||||
| Oct 27, 2020 | |||||||
| Jul 31, 2020 | |||||||
| Apr 28, 2020 | |||||||
| Feb 5, 2020 | |||||||
| Oct 29, 2019 | |||||||
| Jul 30, 2019 | |||||||
| Apr 30, 2019 | |||||||
| Feb 1, 2019 | |||||||
| Oct 25, 2018 | |||||||
| Jul 27, 2018 | |||||||
| May 1, 2018 | |||||||
| Feb 2, 2018 | |||||||
| Oct 27, 2017 | |||||||
| Jul 28, 2017 | |||||||
| May 2, 2017 | |||||||
| Feb 2, 2017 | |||||||
| Oct 25, 2016 | |||||||
| Jul 29, 2016 | |||||||
| May 5, 2016 | |||||||
| Feb 3, 2016 | |||||||
| Oct 27, 2015 | |||||||
| Jul 28, 2015 |